Next Article in Journal
Suppression of Hepatocyte Nuclear Factor 4 α by Long-term Infection of Hepatitis B Virus Contributes to Tumor Cell Proliferation
Next Article in Special Issue
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
Previous Article in Journal
Integrative Transcriptome and Proteome Analysis of the Tube Foot and Adhesive Secretions of the Sea Urchin Paracentrotus lividus
Previous Article in Special Issue
Transgelin, a p53 and PTEN-Upregulated Gene, Inhibits the Cell Proliferation and Invasion of Human Bladder Carcinoma Cells In Vitro and In Vivo
Article

TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients

by 1,2,3,†, 4,†, 1,2,3,†, 2,3, 2,3, 1,2,3, 4 and 1,2,3,*
1
Instituto de Investigação e Inovação em Saúde (i3S), 4200-135 Porto, Portugal
2
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), 4200-135 Porto, Portugal
3
Faculdade de Medicina da Universidade do Porto (FMUP), 4200-319 Porto, Portugal
4
Grupo de Patologia e Terapêutica Experimental, Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), 4200-072 Porto, Portugal
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2020, 21(3), 947; https://doi.org/10.3390/ijms21030947
Received: 28 December 2019 / Revised: 27 January 2020 / Accepted: 30 January 2020 / Published: 31 January 2020
Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Methods — 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, TERT rs2853669 single nucleotide polymorphism, and Fibroblast Growth Factor Receptor 3 (FGFR3) hotspot mutations. Results — TERTp mutations were found in 56.0% of BCG-NMIBC and were not associated with tumor stage or grade. FGFR3 mutations were found in 44.9% of the cases and were not associated with tumor stage or grade nor with TERTp mutations. The TERT rs2853669 single nucleotide polymorphism was associated with tumors of higher grade. The specific c.1-146G>A TERTp mutation was an independent predictor of nonrecurrence after BCG therapy (hazard ratio—0.382; 95% confidence interval—0.150–0.971, p = 0.048). Conclusions — TERTp mutations are frequent in BCG-NMIBC and -146G>A appears to be an independent predictive marker of response to BCG treatment with an impact in recurrence-free survival. View Full-Text
Keywords: TERT promoter mutations; FGFR3; non muscle invasive bladder cancer; BCG therapy TERT promoter mutations; FGFR3; non muscle invasive bladder cancer; BCG therapy
Show Figures

Figure 1

MDPI and ACS Style

Batista, R.; Lima, L.; Vinagre, J.; Pinto, V.; Lyra, J.; Máximo, V.; Santos, L.; Soares, P. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. Int. J. Mol. Sci. 2020, 21, 947. https://doi.org/10.3390/ijms21030947

AMA Style

Batista R, Lima L, Vinagre J, Pinto V, Lyra J, Máximo V, Santos L, Soares P. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients. International Journal of Molecular Sciences. 2020; 21(3):947. https://doi.org/10.3390/ijms21030947

Chicago/Turabian Style

Batista, Rui, Luís Lima, João Vinagre, Vasco Pinto, Joana Lyra, Valdemar Máximo, Lúcio Santos, and Paula Soares. 2020. "TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients" International Journal of Molecular Sciences 21, no. 3: 947. https://doi.org/10.3390/ijms21030947

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop